WeVote
Log In

Bill

Bill

A 4312

Authorizes and directs the commissioner of health to designate HTLV-1 and HTLV-2 communicable diseases; and relates to the HTLV-1 and HTLV-2 viruses

2025 Regular Session Introduced by Joe DeStefano and 3 co-sponsors

Bill A 4312 designates HTLV-1 and HTLV-2 as communicable diseases, enhancing public health measures, awareness, and management for affected patients and providers.

REFERRED TO HEALTH
0
WeVote Research Nonpartisan
Bill Summary · A 4312

Summary of Bill A 4312

Bill Information

  • Bill Number: A 4312
  • Title: Authorizes and directs the commissioner of health to designate HTLV-1 and HTLV-2 communicable diseases; and relates to the HTLV-1 and HTLV-2 viruses
  • Status: Referred to Health
  • Introduced: February 04, 2025
  • Classification: Bill

Purpose and Intent

Bill A 4312 aims to enhance public health measures by officially designating the Human T-Lymphotropic Virus types 1 and 2 (HTLV-1 and HTLV-2) as communicable diseases. This designation is intended to improve awareness, reporting, and management of these viruses, which can lead to serious health complications.

Key Provisions

  • Designation of Communicable Diseases: The bill empowers the commissioner of health to officially classify HTLV-1 and HTLV-2 as communicable diseases. This classification is crucial for public health monitoring and response.
  • Health Guidelines Development: Following the designation, the commissioner will be responsible for developing guidelines for the prevention, diagnosis, and treatment of HTLV-1 and HTLV-2 infections.
  • Reporting Requirements: The bill may establish new reporting requirements for healthcare providers regarding cases of HTLV-1 and HTLV-2, facilitating better tracking and management of these infections.

Affected Parties

  • Public Health Officials: The bill will impact the operations of health departments and officials responsible for disease control and prevention.
  • Healthcare Providers: Doctors and medical facilities will need to adapt to new reporting requirements and guidelines related to HTLV-1 and HTLV-2.
  • Patients: Individuals diagnosed with HTLV-1 or HTLV-2 may benefit from improved healthcare protocols and increased awareness of these viruses.

Procedural Aspects

  • Current Status: As of February 4, 2025, the bill has been referred to the Health Committee for further consideration.
  • Related Legislation: This bill is part of a broader legislative context, with connections to prior-session bills A 7533, A 5675, A 4215, and A 2762, which may address related health issues or communicable diseases.

Conclusion

Bill A 4312 represents a significant step towards improving public health responses to HTLV-1 and HTLV-2. By designating these viruses as communicable diseases, the bill aims to enhance awareness, reporting, and management strategies, ultimately benefiting public health outcomes. Further developments will depend on the committee's review and any subsequent legislative actions.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.